<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01024335</url>
  </required_header>
  <id_info>
    <org_study_id>#5962 DA027124</org_study_id>
    <secondary_id>R01DA027124</secondary_id>
    <secondary_id>DPMC</secondary_id>
    <nct_id>NCT01024335</nct_id>
  </id_info>
  <brief_title>Dronabinol Naltrexone Treatment for Opioid Dependence</brief_title>
  <acronym>Domino</acronym>
  <official_title>Dronabinol Naltrexone Treatment for Opioid Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this two-year study is to test the efficacy of dronabinol as an adjunct to
      maintenance treatment with naltrexone in opioid-dependent individuals. We hypothesize that
      administering dronabinol during detoxification and during the first few weeks of naltrexone
      treatment will lead to improved naltrexone tolerability, resulting in better naltrexone
      compliance and treatment retention, and ultimately a reduction in opioid use and relapse
      rates.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of this two-year study is to test the efficacy of dronabinol as an adjunct to
      maintenance treatment with naltrexone in opioid-dependent individuals. We are proposing a
      randomized, double-blind, placebo controlled, parallel-groups, 8 week study of relapse
      prevention in opioid-dependent individuals. Participants will be randomized into one of two
      conditions (1) Naltrexone and Placebo (N=20) and (2) Naltrexone and dronabinol 15 mg bid
      (N=40). Treatment will be delivered in an outpatient setting except for the initial phase of
      inpatient detoxification, lasting 8 days. A long-acting, injectable form of naltrexone 380 mg
      (Vivitrol) will be administered once per month (the total of two injections), while
      dronabinol or placebo will be taken daily. In addition, patients will receive a psychosocial
      intervention that will include elements of motivational interviewing and cognitive-behavioral
      relapse prevention therapy. The primary aim is to test the efficacy of dronabinol in
      improving tolerability of naltrexone induction and reducing attrition during detoxification
      and the first two months of naltrexone treatment. The primary outcome will be the severity of
      opiate withdrawal and craving. The secondary outcome will be will be retention in treatment
      at study's end.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Opiate Withdrawal Measured by the Subjective Opiate Withdrawal Scale (SOWS) .</measure>
    <time_frame>3x/week during 8 weeks of the trial or study participation</time_frame>
    <description>The Subjective Opiate Withdrawal Scale is a self-administered 16 scale containing 16 symptoms ranging in severity from 0 (not at all) to 4 (extremely). The SOWS total score is the sum of 16 items, ranging from 0 (no opiate withdrawal ) to 64 ( severe opiate withdrawal). Values from multiple assessments during the 8-week outpatient phase were averaged.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Retention</measure>
    <time_frame>retention over 8 weeks.</time_frame>
    <description>Of those participants randomized to the naltrexone and dronabinol arm, the number that completed all 8 weeks of treatment.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Opioid Dependence</condition>
  <arm_group>
    <arm_group_label>Naltrexone and placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A long-acting, injectable form of naltrexone 380 mg (Vivitrol) will be administered once per month while placebo will be taken daily for the first 5 weeks of treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naltrexone and dronabinol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A long-acting, injectable form of naltrexone 380 mg (Vivitrol) will be administered once per month (the total of two injections, once at the end of hospitalization, and once at end of first month of outpatient treatment), while dronabinol (15 mg bid) will be taken daily for the first 5 weeks of treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>injectable naltrexone and dronabinol</intervention_name>
    <description>Injectable form of naltrexone 380 mg (Vivitrol) will be administered once per month plus dronabinol 15 mg bid for the first 5 weeks of treatment.</description>
    <arm_group_label>Naltrexone and dronabinol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone and placebo</intervention_name>
    <description>Injectable form of naltrexone 380 mg (Vivitrol) will be administered once per month plus placebo bid for 5 weeks.</description>
    <arm_group_label>Naltrexone and placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Adult, aged 18-60.

          -  2. Meets Diagnostic and Statistical Manual -IV criteria for current opiate dependence
             disorder of at least six months duration, supported by a positive urine for opiates
             and a positive naloxone challenge test if the diagnosis is unclear.

          -  3. Have a history of marijuana use (more than 30 occasions lifetime)

          -  4. Voluntarily seeking treatment for opioid dependence

          -  5. In otherwise good health based on complete medical history, physical examination,
             vital signs measurement, ECG, and laboratory tests (hematology, blood chemistry,
             urinalysis) within normal ranges.

          -  6. Able to give informed consent.

        Exclusion Criteria:

          -  1. Physiologically dependent on alcohol or sedative-hypnotics with impending
             withdrawal.

          -  2. Patients meeting current criteria for cannabis abuse or dependence, and those who
             used cannabis in the week prior to study entry as documented by the positive
             toxicology

          -  3. Current Diagnostic and Statistical Manual -IV criteria of other substance use
             disorders. Exceptions include cannabis abuse or dependence, nicotine dependence,
             cocaine abuse or dependence, alcohol abuse or alcohol dependence without physiological
             dependence as long as opioid dependence is a primary disorder. Alcohol dependence with
             physiological dependence is exclusionary.

          -  4. Significant current suicidal risk or 1 or more suicide attempts within the past
             year

          -  5. History of accidental drug overdose in the last three years defined as an episode
             of opioid-induced unconsciousness or incapacitation, whether or not medical treatment
             was sought or received.

          -  6. Positive serum pregnancy test, lactation, or unwillingness to use a satisfactory
             method of birth control

          -  7. Active psychiatric disorder which might interfere with participation or make
             participation hazardous, including Diagnostic and Statistical Manual -IV organic
             mental disorder, psychotic disorder, or bipolar disorder with mania

          -  8. History of allergic reaction, adverse reaction, or sensitivity to any study
             medication.

          -  9. Acute hepatitis with serum glutamic-oxaloacetic transaminase or serum
             glutamic-pyruvic transaminase &gt; 3 times the upper end of the laboratory normal range
             (chronic hepatitis is acceptable as we have found naltrexone treatment well tolerate
             and safe among patients with chronic hepatitis)

          -  10. Currently prescribed or regularly taking opiates for chronic pain or medical
             illness.

          -  11. Current participation in a methadone maintenance treatment program and/or regular
             use of illicit methadone (&gt;30 mg per week).

          -  12. Current participation in another intensive psychotherapy or substance abuse
             treatment program or participation in another treatment study.

          -  13. Concurrent treatment with psychotropic medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adam Bisaga, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York State Psychiatric Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2009</study_first_submitted>
  <study_first_submitted_qc>November 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2009</study_first_posted>
  <results_first_submitted>April 28, 2014</results_first_submitted>
  <results_first_submitted_qc>September 3, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 5, 2014</results_first_posted>
  <last_update_submitted>September 3, 2014</last_update_submitted>
  <last_update_submitted_qc>September 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>opioid dependence</keyword>
  <keyword>naltrexone</keyword>
  <keyword>vivitrol</keyword>
  <keyword>dronabinol</keyword>
  <keyword>marinol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Analgesics, Opioid</mesh_term>
    <mesh_term>Naltrexone</mesh_term>
    <mesh_term>Dronabinol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Naltrexone and Placebo</title>
          <description>A long-acting, injectable form of naltrexone 380 mg (Vivitrol) will be administered once per month while placebo will be taken daily for the first 5 weeks of treatment.
Naltrexone and placebo: Injectable form of naltrexone 380 mg (Vivitrol) will be administered once per month plus placebo bid for 5 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Naltrexone and Dronabinol</title>
          <description>A long-acting, injectable form of naltrexone 380 mg (Vivitrol) will be administered once per month (the total of two injections, once at the end of hospitalization, and once at end of first month of outpatient treatment), while dronabinol (15 mg bid) will be taken daily for the first 5 weeks of treatment.
Injectable naltrexone and dronabinol: Injectable form of naltrexone 380 mg (Vivitrol) will be administered once per month plus dronabinol 15 mg bid for the first 5 weeks of treatment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Naltrexone and Placebo</title>
          <description>A long-acting, injectable form of naltrexone 380 mg (Vivitrol) will be administered once per month while placebo will be taken daily for the first 5 weeks of treatment.
Naltrexone and placebo: Injectable form of naltrexone 380 mg (Vivitrol) will be administered once per month plus placebo bid for 5 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Naltrexone and Dronabinol</title>
          <description>A long-acting, injectable form of naltrexone 380 mg (Vivitrol) will be administered once per month (the total of two injections, once at the end of hospitalization, and once at end of first month of outpatient treatment), while dronabinol (15 mg bid) will be taken daily for the first 5 weeks of treatment.
Injectable naltrexone and dronabinol: Injectable form of naltrexone 380 mg (Vivitrol) will be administered once per month plus dronabinol 15 mg bid for the first 5 weeks of treatment.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.3" spread="11.1"/>
                    <measurement group_id="B2" value="38.5" spread="11.6"/>
                    <measurement group_id="B3" value="38.1" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Opiate Withdrawal Measured by the Subjective Opiate Withdrawal Scale (SOWS) .</title>
        <description>The Subjective Opiate Withdrawal Scale is a self-administered 16 scale containing 16 symptoms ranging in severity from 0 (not at all) to 4 (extremely). The SOWS total score is the sum of 16 items, ranging from 0 (no opiate withdrawal ) to 64 ( severe opiate withdrawal). Values from multiple assessments during the 8-week outpatient phase were averaged.</description>
        <time_frame>3x/week during 8 weeks of the trial or study participation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Naltrexone and Placebo</title>
            <description>A long-acting, injectable form of naltrexone 380 mg (Vivitrol) will be administered once per month while placebo will be taken daily for the first 5 weeks of treatment.
Naltrexone and placebo: Injectable form of naltrexone 380 mg (Vivitrol) will be administered once per month plus placebo bid for 5 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Naltrexone and Dronabinol</title>
            <description>A long-acting, injectable form of naltrexone 380 mg (Vivitrol) will be administered once per month (the total of two injections, once at the end of hospitalization, and once at end of first month of outpatient treatment), while dronabinol (15 mg bid) will be taken daily for the first 5 weeks of treatment.
Injectable naltrexone and dronabinol: Injectable form of naltrexone 380 mg (Vivitrol) will be administered once per month plus dronabinol 15 mg bid for the first 5 weeks of treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Opiate Withdrawal Measured by the Subjective Opiate Withdrawal Scale (SOWS) .</title>
          <description>The Subjective Opiate Withdrawal Scale is a self-administered 16 scale containing 16 symptoms ranging in severity from 0 (not at all) to 4 (extremely). The SOWS total score is the sum of 16 items, ranging from 0 (no opiate withdrawal ) to 64 ( severe opiate withdrawal). Values from multiple assessments during the 8-week outpatient phase were averaged.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.16" spread="6.13"/>
                    <measurement group_id="O2" value="13.36" spread="10.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Retention</title>
        <description>Of those participants randomized to the naltrexone and dronabinol arm, the number that completed all 8 weeks of treatment.</description>
        <time_frame>retention over 8 weeks.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Naltrexone and Placebo</title>
            <description>A long-acting, injectable form of naltrexone 380 mg (Vivitrol) will be administered once per month while placebo will be taken daily for the first 5 weeks of treatment.
Naltrexone and placebo: Injectable form of naltrexone 380 mg (Vivitrol) will be administered once per month plus placebo bid for 5 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Naltrexone and Dronabinol</title>
            <description>A long-acting, injectable form of naltrexone 380 mg (Vivitrol) will be administered once per month (the total of two injections, once at the end of hospitalization, and once at end of first month of outpatient treatment), while dronabinol (15 mg bid) will be taken daily for the first 5 weeks of treatment.
Injectable naltrexone and dronabinol: Injectable form of naltrexone 380 mg (Vivitrol) will be administered once per month plus dronabinol 15 mg bid for the first 5 weeks of treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Retention</title>
          <description>Of those participants randomized to the naltrexone and dronabinol arm, the number that completed all 8 weeks of treatment.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Naltrexone and Placebo</title>
          <description>A long-acting, injectable form of naltrexone 380 mg (Vivitrol) will be administered once per month while placebo will be taken daily for the first 5 weeks of treatment.
Naltrexone and placebo: Injectable form of naltrexone 380 mg (Vivitrol) will be administered once per month plus placebo bid for 5 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Naltrexone and Dronabinol</title>
          <description>A long-acting, injectable form of naltrexone 380 mg (Vivitrol) will be administered once per month (the total of two injections, once at the end of hospitalization, and once at end of first month of outpatient treatment), while dronabinol (15 mg bid) will be taken daily for the first 5 weeks of treatment.
Injectable naltrexone and dronabinol: Injectable form of naltrexone 380 mg (Vivitrol) will be administered once per month plus dronabinol 15 mg bid for the first 5 weeks of treatment.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritis and facial swelling</sub_title>
                <description>A participant in the dronabinol treatment arm developed symptoms of pruritis and facial swelling two days after receiving an injection of naltrexone. A dermatologist determined that the rash was most likely not related to the study medication.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <description>One participant in the placebo arm was hospitalized for symptoms of dehydration during the first week of the outpatient phase.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Kidney infection and dislocated arm</sub_title>
                <description>A participant in the placebo arm was hospitalized for treatment of a kidney infection and dislocated arm, which occurred 3 weeks after discontinuation of study participation</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea/vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>GI Distress</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Increased/decreased appetite</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Body Aches</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Sweating/chills</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="20"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Mood changes</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Adam Bisaga</name_or_title>
      <organization>NYS Psychiatric Institute</organization>
      <phone>646-774-6155</phone>
      <email>amb107@columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

